1,044 research outputs found
MODASC: ASIC for mobile data acquisition systems using satellite communications
MODASC is an ASIC that performs wide area mobile data acquisition using satellite communication to provide global coverage. This circuit provides two operation modes: an autonomous mode, that periodically establishes connection with the control center, and a slave mode, working as a peripheral connected to a general purpose micro controller. This experiment has been realized under FUSE special action in collaboration with SAINSEL
Bioactive pectic polysaccharides from bay tree pruning waste: Sequential subcritical water extraction and application in active food packaging
The potential isolation of bio-active polysaccharides from bay tree pruning waste was studied using sequential subcritical water extraction using different time-temperature combinations. The extracted polysaccharides were highly enriched in pectins while preserving their high molecular mass (10–100 kDa), presenting ideal properties for its application as additive in food packaging. Pectin-enriched chitosan films were prepared, improving the optical properties (=95% UV-light barrier capacity), antioxidant capacity (?95% radical scavenging activity) and water vapor permeability (=14 g·Pa-1·s-1·m-1·10-7) in comparison with neat chitosan-based films. Furthermore, the antimicrobial activity of chitosan was maintained in the hybrid films. Addition of 10% of pectins improved mechanical properties, increasing the Young's modulus 12%, and the stress resistance in 51%. The application of pectin-rich fractions from bay tree pruning waste as an additive in active food packaging applications, with triple action as antioxidant, barrier, and antimicrobial has been demonstrated.Authors would like to thank the Spanish Ministry of Science and
Innovation (Ramon y Cajal contract RYC-2015-17109) and Universidad
de Cordoba, ´ Spain (Predoctoral Grant 2019) for the financial support
during this work
Manuel Vázquez Montalbán. Guías didácticas y de lectura para ESO y Bachillerato
Podeu consultar la versió en català a: http://hdl.handle.net/2445/11088
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
Rituximab is a standard treatment for non-Hodgkin diffuse large B-cell
(DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was
developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration-related reactions (ARRs). MabRella was a phase IIIb trial to assess the safety
of switching from intravenous to subcutaneous administration of rituximab
during first-line induction/maintenance for DLBCL or FL, focusing on
ARRs. Efficacy, satisfaction and quality of life were also assessed. Patients
received subcutaneous rituximab plus standard induction chemotherapy for
DLBCL or FL for 4–7 cycles, and/or every 2 months maintenance
monotherapy for FL for 6–12 cycles. The study included 140 patients:
DLBCL, n = 29; FL, n = 111. Ninety-five percent of patients experienced
adverse events, reaching grade ≥3 in 38 6% and were serious in 30 0%.
AARs occurred in 48 6%, mostly (84 9%) at the injection site, with only
2 1% of patients reaching grade 3. The end-of-induction complete/unconfirmed complete response rate was 69 6%. After a median follow-up of
33 5 months, median disease-/event-/progression-free and overall survivals
were not attained. The Rituximab Administration Satisfaction Questionnaire showed improvements in overall satisfaction and the EuroQoL-5D a
good quality-of-life perception at induction/maintenance end. Therefore,
switching to subcutaneous rituximab showed no new safety issues and
maintained efficacy with improved satisfaction and quality of life
Manuel Vázquez Montalbán. Guies didàctiques i de lectura per a ESO i Batxillerat
Podeu consultar la versió en castellà a: http://hdl.handle.net/2445/10821
Identification of Marine Biotechnology Value Chains with High Potential in the Northern Mediterranean Region
© 2023. The authors. This document is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by /4.0/
This document is the Accepted version of a Published Work that appeared in final form in Marine Drugs. To access the final edited and published work see https://doi.org/10.3390/md21070416Marine (blue) biotechnology is an emerging field enabling the valorization of new products and processes with massive potential for innovation and economic growth. In the Mediterranean region, this innovation potential is not exploited as well as in other European regions due to a lack of a clear identification of the different value chains and the high fragmentation of business innovation initiatives. As a result, several opportunities to create an innovative society are being missed. To address this problem, eight Northern Mediterranean countries (Croatia, France, Greece, Mar. Drugs 2023, 21, 416. https://doi.org/10.3390/md21070416 https://www.mdpi.com/journal/marinedrugs Mar. Drugs 2023, 21, 416 2 of 26 Italy, Montenegro, Portugal, Slovenia and Spain) established five national blue biotechnology hubs to identify and address the bottlenecks that prevent the development of marine biotechnology in the region. Following a three-step approach (1. Analysis: setting the scene; 2. Transfer: identification of promising value chains; 3. Capitalization: community creation), we identified the three value chains that are most promising for the Northern Mediterranean region: algae production for added-value compounds, integrated multi-trophic aquaculture (IMTA) and valorization aquaculture/fisheries/processing by-products, unavoidable/unwanted catches and discards. The potential for the development and the technical and non-technical skills that are necessary to advance in this exciting field were identified through several stakeholder events which provided valuable insight and feedback that should be addressed for marine biotechnology in the Northern Mediterranean region to reach its full potential
Identification of Marine Biotechnology Value Chains with High Potential in the Northern Mediterranean Region
©2023. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/
This document is the Published, version of a Published Work that appeared in final form in Marine Drugs. To access the final edited and published work see https://doi.org/ 10.3390/md21070416Marine (blue) biotechnology is an emerging field enabling the valorization of new products
and processes with massive potential for innovation and economic growth. In the Mediterranean
region, this innovation potential is not exploited as well as in other European regions due to a
lack of a clear identification of the different value chains and the high fragmentation of business
innovation initiatives. As a result, several opportunities to create an innovative society are being
missed. To address this problem, eight Northern Mediterranean countries (Croatia, France, Greece Italy, Montenegro, Portugal, Slovenia and Spain) established five national blue biotechnology hubs
to identify and address the bottlenecks that prevent the development of marine biotechnology in
the region. Following a three-step approach (1. Analysis: setting the scene; 2. Transfer: identifi cation of promising value chains; 3. Capitalization: community creation), we identified the three
value chains that are most promising for the Northern Mediterranean region: algae production for
added-value compounds, integrated multi-trophic aquaculture (IMTA) and valorization aquacul ture/fisheries/processing by-products, unavoidable/unwanted catches and discards. The potential
for the development and the technical and non-technical skills that are necessary to advance in this
exciting field were identified through several stakeholder events which provided valuable insight
and feedback that should be addressed for marine biotechnology in the Northern Mediterranean
region to reach its full potential
- …